Next Capital Management’s ADMA Biologics ADMA Stock Holding History

Next Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-79	Closed	–	–	96
2019 Q3	$0	Buy	+79	New	+$330	﹤0.01%	260

Other funds holding ADMA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MWVC

Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return

Next Capital Management's ADMA Position: Q4 2019 in Review

Next Capital Management sold out of ADMA Biologics (ADMA) in Q4 2019, closing a stake of 79 shares.

Next Capital Management first reported a position in ADMA in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 74 funds tracked by Wall St. Rank hold ADMA as of Q4 2019.

Next Capital Management reported no remaining ADMA Biologics position as of Q4 2019 after selling out during the quarter.
Next Capital Management sold 79 ADMA Biologics shares in Q4 2019.
Next Capital Management first reported a position in ADMA Biologics in Q3 2019 and held it in 1 quarter.
Next Capital Management's ADMA Biologics position peaked at $0 in Q3 2019.
74 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2019.

Based on Next Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.